Arthritis Clinical Trial
Official title:
Pharmacokinetics and Metabolism of [14C] BMS-986142 in Healthy Male Subjects
Verified date | November 2016 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is an open-label, single-dose, study in healthy males. The primary objective is to assess the pharmacokinetics (PK), metabolism, and routes of elimination of a single oral dose of radiolabeled BMS-986142 in healthy male subjects.
Status | Completed |
Enrollment | 9 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Signed Informed Consent - Target population: Healthy males with no clinically significant deviations from normal in medical history, physical examinations, vital signs, electrocardiograms (ECGs), physical measurements, and clinical laboratory tests - Body weight of at least 50 kilograms (110 pounds); body mass index (BMI) between 18 to 32 kg/m2. Exclusion Criteria: - History of any chronic or acute illness including active TB in the last 3 years, recent infection, gastrointestinal disease, smoking within less than 6 months prior to dosing, alcohol abuse, inability to tolerate oral medication, or inability to be venipunctured. - Vaccination or plans for vaccination with any live vaccine 12 weeks prior to first dose of study drug, during the course of the study, or 30 days after the last dose of study drug. - Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiograms, or clinical laboratory determinations beyond what is consistent with the target population. - History of allergies and adverse drug reaction to any oral contraceptive compounds or Bruton tyrosine kinase (BTK) inhibitors. - Participated in a radiolabeled drug study within the previous 12 months; clinically significant diagnostic or therapeutic radiation exposure within the previous 12 months; or current employment in a job requiring radiation exposure monitoring. |
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Covance Clinical Research Unit | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint is PK parameters that will be determined from plasma concentration versus time | Day 1 to Day 13 | No | |
Primary | Urinary/fecal/bile (if applicable) TRA (Total radioactivity) recovery data | Day 1 to Day 13 | No | |
Secondary | Safety endpoints include the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and the results of electrocardiogram tests (ECGs), vital signs, physical exams, and clinical laboratory tests. | Day 1 to Day 13 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04228458 -
ThermRheum Version 1
|
N/A | |
Withdrawn |
NCT04976972 -
A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation
|
N/A | |
Completed |
NCT04037436 -
Functional Exercise and Nutrition Education Program for Older Adults
|
N/A | |
Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
Completed |
NCT02944448 -
A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee
|
Phase 2 | |
Recruiting |
NCT02498808 -
Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?
|
N/A | |
Recruiting |
NCT02777060 -
Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures
|
N/A | |
Enrolling by invitation |
NCT02487888 -
A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care
|
N/A | |
Withdrawn |
NCT02136251 -
Total Shoulder Replacement Outcomes With Autologous Bone Graft as Fixator for Glenoid Anchor Peg.
|
||
Completed |
NCT02143206 -
Modifying Exercise for the COPD Patient
|
||
Completed |
NCT01407874 -
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
|
Phase 2 | |
Completed |
NCT01285843 -
Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component
|
N/A | |
Completed |
NCT01172327 -
Self-Directed Exercise Program for Adults With Arthritis
|
N/A | |
Completed |
NCT00987870 -
Safety and Efficacy of BFH772 in Psoriasis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00750984 -
A Comparison of Two Different Surgical Techniques for Total Hip Resurfacing
|
N/A | |
Completed |
NCT01184924 -
Evaluation of the Arthritis Foundation Tai Chi Program
|
N/A | |
Active, not recruiting |
NCT00611585 -
A Safety and Efficacy Study of the Birmingham Hip Resurfacing System
|
N/A | |
Completed |
NCT00379184 -
Sensitization in Osteoarthritic Knees
|
N/A | |
Completed |
NCT00175448 -
Comparison of Physiotherapy Versus Home Exercise Following Hip Replacement Surgery
|
N/A | |
Completed |
NCT00403676 -
Nursing Consultation in Out-patient Clinics for Patients With Inflammatory Rheumatic Disease
|
N/A |